Biotech

ProMetic Life Sciences has a huge upside, Paradigm Capital says

Biopharmaceutical company ProMetic Life Sciences (ProMetic Life Sciences Stock Quote, Chart TSX:PLI) has received the green light from the US FDA concerning the manufacturing protocol for its therapeutic protein Ryplazim (plasminogen), an event which analyst Rahul Sarugaser of Paradigm Capital call ...

Pharmaceutical Portfolio Management Reading List

This article was originally published at https://www.drugpatentwatch.com/blog/pharmaceutical-portfolio-management-reading-list/ Portfolio, Program, and Project Management in the Pharmaceutical and Biotechnology Industries This book describes the way that pharmaceutical projects and programs are cur ...

Tetra Bio-Pharma has 56 per cent upside, Paradigm Capital says

Biopharmaceutical company Tetra Bio-Pharma (Tetra Bio-Pharma Stock Quote, Chart TSXV:TBP) has a potential turning point in its proposed clinical program to treat fibromyalgia, says analyst Rahul Sarugaser of Paradigm Capital. In a research update on Friday, Sarugaser reiterated his “Buy” rating ...

Securing the Right Space for Your Biotech Start-up

This is a guest post by Steven Lee, Senior Scientist in the Life Sciences Group at Environmental Health & Engineering (EH&E) Once you have the idea and the funding for a biotech start-up, you may think the biggest challenges are behind you. However, without proper planning and considerations, the ...

Evidence of insufficient quality of reporting in patent landscapes in the life sciences

This article was originally published at https://www.drugpatentwatch.com/blog/evidence-of-insufficient-quality-of-reporting-in-patent-landscapes-in-the-life-sciences/ This article was originally published by James A Smith, Zeeshaan Arshad, Hannah Thomas, Andrew J Carr & David A Brindley in Nature B ...

Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks

This article was originally published at https://www.drugpatentwatch.com/blog/addressing-the-challenge-of-high-priced-prescription-drugs-in-the-era-of-precision-medicine-a-systematic-review-of-drug-life-cycles-therapeutic-drug-markets-and-regulatory-frameworks/ This paper was originally published b ...

Gain Intelligence on Royalties, Settlements, and More with Drug Patent Litigation Information

Disclosure: the majority of the companies mentioned below are, or have been, clients of DrugPatentWatch Drug patent litigation can be used for many aspect of biopharmaceutical business strategy. Many parties… The post Gain Intelligence on Royalties, Settlements, and More with Drug Patent Litigatio ...

Q2 2018 Share Price Performance

Analysis: Healthcare Outperforms the Market (For the Second Quarter in a Row) In this blog post, the Bloom Burton equity research team summarizes the performance of the Canadian healthcare sector during 2Q-2018, and provides commentary on select stock movements and overall market trends. Inclusio ...

Canada in Science – August 3, 2018

Welcome to your Canada in Science Review for August 3rd, 2018! Nat Genet.  2018 Jul 16. doi: 10.1038/s41588-018-0168-y Common Variation Near IRF6 is Associated with IFN-β–Induced Liver Injury in Multiple Sclerosis. Nature.  2018 Jul;559(7713):285-289. CRISPR Screens Identify Genomic Ribon ...

Two of these three Canadian ETFs are buys

Here are three ETFs that mostly hold high-quality stocks widely traded on Canadian exchanges. Each fund mirrors the performance of a major stock index or sub-index.  That’s different from ETFs focused on narrower indexes or themes such as biotechnology or solar power. While you do pay brokerage ...